Skip to main content

Cutaneous Small-Vessel Vasculitis following Direct Oral Anticoagulants (DOACs), Warfarin, or Allopurinol Use in Patients with Atrial Fibrillation: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
allopurinol
direct oral anticoagulant (DOAC)
warfarin
Health Outcome(s)
cutaneous small-vessel vasculitis
Description

The purpose of this request was to calculate the number of treated patients and time to treatment among patients exposed to either direct oral anticoagulants (DOACs), warfarin, or allopurinol who had a prior diagnosis of atrial fibrillation in the Sentinel Distributed Database (SDD). The outcomes of interest were cutaneous small‐vessel vasculitis (CSVV) followed by a treatment of prednisone or prednisolone or steroid medication within 90 days.

The study period included data from October 19, 2010 to December 31, 2018. We distributed this request to 17 Data Partners on February 10, 2020.

Deliverables (1)
Sentinel Modular Program Report: Cutaneous Small-Vessel Vasculitis following Direct Oral Anticoagulants (DOACs), Warfarin, or Allopurinol Use in Patients with Atrial Fibrillation: A Descriptive Analysis